RxDoctor Payments Data

Zachary Shook, MD

Internal Medicine · Richmond, VANPI 1386690220

Payments from drug & device makers

$12,889in general payments, 2019–2025

Across 840 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Amgen$1K
  • Boehringer Ingelheim$808
  • AstraZeneca$760
  • Lilly USA, LLC$600
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,844100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)119$1,763
Novo Nordisk119$1,588
Amgen(2 entities)85$1,299
Boehringer Ingelheim52$808
AstraZeneca26$760
Lilly USA, LLC42$600
GSK55$577
Pfizer46$565
Amarin Pharma, Inc.26$470
Novartis30$416
Abbott24$411
Merck28$390
Boston Scientific7$174
Esperion Therapeutics, Inc.10$155
Insightec,inc2$150
Johnson & Johnson17$146
Regeneron Healthcare Solutions, Inc.5$144
Takeda Pharmaceuticals U.S.A., Inc.15$139
Astellas Pharma US Inc8$133
Biohaven Pharmaceutical Holding Company Ltd.6$123
Actelion Pharmaceuticals US, Inc.6$118
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$104
Genentech USA, Inc.7$99
Inspire Medical Systems, Inc.3$97
Otsuka America Pharmaceutical, Inc.4$88
Phathom Pharmaceuticals, Inc.5$87
Nestle Healthcare Nutrition Inc.5$76
Baxter Healthcare2$74
Biohaven Pharmaceuticals, Inc.4$73
Antares Pharma, Inc.4$71
Daiichi Sankyo Inc.3$66
Eisai Inc.4$66
Ironwood Pharmaceuticals, Inc4$61
Kowa Pharmaceuticals America, Inc.4$53
Gilead3$49
Supernus Pharmaceuticals, Inc.3$49
Edwards Lifesciences3$48
Bayer3$47
Xeris Pharmaceuticals, Inc.2$44
Irhythm Technologies, Inc.2$42
Sanofi-aventis U.S. LLC3$40
Mannkind Corporation2$32
Mylan Specialty L.p.2$32
Tolmar, Inc.2$31
Ionis Pharmaceuticals, Inc.1$30
Teva Pharmaceuticals USA, Inc.2$29
Jazz Pharmaceuticals Inc.2$28
Dynavax Technologies Corporation1$26
Shire North American Group Inc2$26
Radius Health, Inc.1$25
Mallinckrodt Hospital Products Inc.1$24
Impulse Dynamics (USA) Inc.1$23
Bausch Health US, LLC1$22
Halozyme Inc1$20
Endo Pharmaceuticals Inc.1$19
Vanda Pharmaceuticals Inc.1$19
Sanofi1$18
Philips North America LLC1$18
Sumitomo Pharma America, Inc.1$18
Axsome Therapeutics, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,889 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$203,233
Medicare patients
610
Services billed
2,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin133$124,877
OzempicSemaglutide54$79,727
EliquisApixaban61$63,951
TrulicityDulaglutide41$54,772
Repatha SureclickEvolocumab62$40,559
FarxigaDapagliflozin Propanediol25$37,186
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$34,824
Praluent PenAlirocumab14$19,703
WegovySemaglutide12$15,902
JanuviaSitagliptin Phosphate12$15,581
NexletolBempedoic Acid20$14,610
MyrbetriqMirabegron22$11,705
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$11,472
Rosuvastatin Calcium769$9,939
Breo ElliptaFluticasone/Vilanterol14$9,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$808$124,877133 claims
Novo NordiskOzempic, Wegovy$1,588$95,62966 claims
PfizerEliquis, Paxlovid$565$66,81096 claims
Lilly USA, LLCTrulicity$600$54,77241 claims
GSKTrelegy Ellipta, Breo Ellipta$577$44,31042 claims
AstraZenecaFarxiga, Symbicort$760$43,72545 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$155$19,31432 claims
MerckJanuvia$390$15,58112 claims
Astellas Pharma US IncMyrbetriq$133$11,70522 claims
AbbVieSynthroid$1,763$4,341109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →